Increased Risk of Chronic Sinusitis in Adults With Gastroesophageal Reflux Disease
A Nationwide Population-Based Cohort Study

Yu-Hsuan Lin, MD, Ting-Shou Chang, MD, Yi-Chien Yao, and Ying-Chun Li, PhD

Abstract: Although gastroesophageal reflux disease (GERD) has been reported to coexist with chronic rhinosinusitis (CRS), it remains controversial whether it increases risk of CRS in adults. This study assesses risk of CRS in adults with newly diagnosed GERD.

We identified 15,807 adult patients with newly diagnosed GERD from Taiwan’s National Health Insurance Research Database for January 1, 2006 to December 31, 2009. We also randomly selected 47,421 subjects without this disease and matched them with patients by age, sex, index year, and comorbidity to create a control cohort. A Cox proportional hazards model was conducted to estimate the development of CRS, including CRS without nasal polyps and CRS with nasal polyps.

Subjects were followed for a median of 2.12 years. In total, CRS developed in 964 (1.52%) of the subjects: 406 patients with GERD (2.57%) and 558 without it (1.18%). After adjustment, those with GERD were found to have a 2.36 times greater risk of CRS (95% confidence interval = 2.08–2.68; P < .001). Risk of this CRS without nasal polyps was higher than the disease with polyps (adjusted hazard ratio: 2.48 vs 1.85).

The individuals with GERD in this study were at significantly greater risk of CRS, most often without nasal polyps. (Medicine 94(39):e1642)

INTRODUCTION
Gastroesophageal reflux disease (GERD), which is more prevalent in western populations, is also a prevalent disorder affecting 2.5% to 7.8% of the people in East Asia.1,2 It is a disorder characterized by reflux of stomach contents causing disturbing symptoms and/or complications.3 Clinically, this disease encompasses not only classical esophageal syndrome but also an assortment of extraesophageal syndromes (EESs) including asthma, reflux cough, and chronic laryngitis.1–5 In United States, the costs of caring for patients with EES are greater than caring for patients that have typical GERD alone.6 Because EESs do not necessarily occur with typical reflux symptoms,5,6 it is difficult to determine whether a symptom is a part of EES or an independent disease.

Chronic rhinosinusitis (CRS) is a group of disorders characterized by inflammation of sinonasal mucosa lasting for more than twelve weeks.7–9 Clinically, it is often subgrouped into CRS without and with nasal polyps,7,9 the latter characterized by intense eosinophilic infiltration and a skewing toward Th2 cytokine expression.10 CRS affects people of all ages, and rivals asthma and diabetes mellitus in prevalence.11,12 Due to its clustering of symptoms and chronicity, this disease has been associated with impaired health-related quality of life, emotional impairment, and functional limitation.12,13 The socioeconomic burden it poses from direct and indirect costs is large.12,13 Though the underlying etiology and pathogenesis of CRS remain largely unknown, it has been associated with a host of comorbidities, including GERD, particularly in investigations of children in studies with great statistical power.14–18 It is unclear whether gastroesophageal reflux disease increases the risk of chronic rhinosinusitis (CRS) in adults. Although some studies have found that it predicts the onset of CRS,19–23 others have not.24–27 Most of these studies, unfortunately, are limited by either small sample sizes, differences in study populations, or unsound diagnostic methods.19–25 Therefore, we conducted a large-scale population-based cohort study in Taiwan to investigate the subsequent risk of CRS without nasal polyps and CRS with nasal polyps after a diagnosis of GERD.

METHODS AND MATERIAL

Ethical Consideration
This study was approved by the Institutional Review Board of Kaohsiung Veterans General Hospital. Review board
requirements for written informed consent were waived because all personal identifying information had been removed from the dataset before analysis.

**Database**

The study samples were retrieved from the Longitudinal Health Insurance Database 2010 (LHID 2010). The National Health Insurance (NHI) program of Taiwan is a mandatory universal health insurance program offering comprehensive and easily accessible medical care to all Taiwanese residents. Its coverage rate has exceeded 99% since March 1, 1995. The National Health Insurance Research Database (NHIRD) consists of original insurance claims data maintained by National Health Research Institute (NHRI) of Taiwan. The NHIRD’s accuracy has been validated and found to be a reliable source of data for research purposes. The LHID 2010, a subset of NHIRD, is a representative database of 1,000,000 subjects who were alive during 2010 and randomly sampled from the registry of all NHI enrollees from 2006 onwards. Detailed information about the database is available online at: http://nhird.nhri.org.tw/.

**Study Design and Participants**

In this retrospective cohort study, we enrolled a cohort of 15,807 adult subjects (older than 18 years) who were newly diagnosed as having GERD (International Classification of Diseases, 9th revision, Clinical Modification [ICD-9-CM] codes: 530.11 or 530.81) and who subsequently received proton pump inhibitor (PPI) for treatment of that disease between January 1, 2007 and December 31, 2009 from the LHID 2010. The date on which the diagnosis of GERD was recorded in the Registry was defined as the index date. This diagnosis was validated by the prescription of PPI because Taiwan’s Bureau of NHI only reimburses PPI for patients with GERD confirmed by panendoscopy or 24-hour pH-meter monitoring. We created a control group of 47,421 patients without GERD from the remaining beneficiaries of LHID 2010. We used propensity score matching to match patients and controls by sex, age strata (18–44, 45–64, 65–74, 75–84, ≥85 years), index year, and comorbidity types. The selected comorbidities for which the subjects were matched are recognized to be common premorbid illness of CRS, including asthma (ICD-9-CM code: 493.X), allergic rhinitis (AR) (ICD-9-CM code: 477.X), otitis media (OM) (ICD-9-CM code: 382.X), adenotonsillitis (ICD-9-CM codes: 474.0X or 474.1X), atopic dermatitis (AD) (ICD-9-CM code: 691.8), and pneumonia (ICD-9-CM code: 480–486). In both groups, subjects with a prior diagnosis of GERD, CRS (ICD-9-CM codes: 473.X or 471.X), human immunodeficiency virus infection (ICD-9-CM code: 042), or primary immune deficiency (ICD-9-CM code: 279.X) before the index date were excluded. Ultimately, 63,228 subjects were enrolled. The flowchart for the selection process is shown in Figure 1.

**Main Outcome Measures**

The primary endpoint of the present study was a subsequent diagnosis of CRS, including CRS without nasal polyps and CRS with nasal polyps, during the study period following the GERD index date. A diagnosis of CRS was defined as diagnosis of CRS without nasal polyps followed by at least one NHI ambulatory care visit (including hospital and clinic outpatient visits). The diagnosis was certified by an otolaryngologist experienced in airway endoscopic examinations, including sinoscopy, nasal endoscopy, flexible laryngoscopy, and sinus surgery.

**Statistical Analysis**

All statistical analyses were performed using SAS software version 9.3 (SAS Institute, Cary, NC) and STATA software package version 12.0 (Stata Corp., College Station, TX). Pearson χ² tests were used to explore the differences between categorical variables and t test for continuous variables between cases and controls. We accessed the cumulative incidence of CRS using Kaplan–Meier analysis and calculated CRS incidence rates (per 10,000 person-years). Differences between cumulative curves was compared using the log-rank test. Risk of CRS following a diagnosis of GERD between the 2 cohorts was performed Cox proportional hazard regressions (stratified by gender, age strata and index year), using the controls as the reference group. Furthermore, we explored individual adjusted hazard ratios (HRs) for CRS with and without nasal polyps in both cohorts. Multiple regression analysis was performed to identify independent risk factors in GERD patients with CRS without nasal polyps and CRS with nasal polyps, respectively. A 2-tailed P-value <0.05 was considered significant.

**RESULTS**

**Characteristics of Study Population**

This study identified 15,807 patients newly diagnosed with GERD (mean age = 50.87 years, standard deviation [SD] = 16.25) and 47,421 match controls (mean age = 49.47 years, SD = 17.58 years) for the 2007–2009 study period. Most patients (42.62%) were aged 45 to 64 years, and asthma and AR were the most common comorbidities (66.0% and 16.26%, respectively). There were no significant statistical differences between the 2 cohorts with regard to age, sex, and comorbidity types (Table 1). However, there was a difference in duration of follow-up, which was longer in the non-GERD population without nasal polyps (P = 0.0239) (Table 1).

**Incidence of CRS**

Out of the 63,228 patients and controls, 964 (1.52%) were diagnosed as having CRS over a mean follow-up period of 2.12 years (95% confidence interval [CI] = 1.94–2.24). A total of 406 (0.64%) patients with GERD and 558 (0.88%) of the controls developed CRS during the follow-up period. Seven hundred seventy-one of the 964 patients that developed CRS did not have nasal polyps. A greater percentage of the patients with GERD had CRS without nasal polyps than did the control group (2.12% vs 0.92%) (Table 2). The incidence rates of CRS without nasal polyps in the GERD patients and control groups

---

*Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.*
were 48.80 and 19.59 persons per 10,000 person-years. GERD patients were at significantly higher risk of CRS without nasal polyps than the controls (log rank test, \( P < 0.001 \)) (Fig. 2).

Patients with GERD had a higher prevalence of CRS with nasal polyps than those without (0.45% vs 0.26%) (Table 2). The incidence rates were 10.24 and 5.45 per 10,000 person-years, respectively (Fig. 3). The result of our Kaplan-Meier analysis of the cumulative incidence of CRS with nasal polyps shows it to be significantly higher for patients with GERD than those without (log rank test, \( P < 0.001 \)).

**Association Between GERD and Risk of CRS**

The adjusted HRs for CRS in general, CRS without nasal polyps, and CRS with nasal polyps in patients with GERD were 2.36 (95% CI = 2.08–2.68; \( P < 0.001 \)), 2.48 (95% CI = 2.15–2.86; \( P < 0.001 \)), and 1.85 (95% CI = 1.37–2.48; \( P < 0.001 \)), respectively, after controlling for age, sex, and comorbidities (Table 2). Patients with GERD were at risk for subsequent CRS, and they were at greater risk of CRS without nasal polyps than CRS with nasal polyps.

The results of our multivariate regression analysis showed that our GERD population had higher adjusted HRs for both CRS without and with nasal polyps in the age category of 45 to 64 years (adjusted HR = 1.59, 95% CI = 1.24–2.04 vs adjusted HR = 1.94, 95% CI = 1.09–3.44, respectively) and comorbid AR (adjusted HR = 3.15, 95% CI = 2.50–3.96 vs. adjusted HR = 2.34, 95% CI = 1.39–3.94, respectively) compared with reference groups. In addition, male patients with GERD had a 2.16-fold (95% CI = 1.31–3.58; \( P < .01 \)) higher risk of CRS with nasal polyps than their female counterparts (Tables 3 and 4).

**DISCUSSION**

This study found an independent association between newly diagnosed GERD and risk of subsequent development of CRS and estimated the risk for subsequent development of CRS in adult GERD patients. To the best of our knowledge, this is the first study to investigate the association of GERD and CRS in adults in an East Asian population. It contributes to large-scale epidemiological data regarding this association from a Chinese population to the prevailing western population studies.

Pediatric studies have found a strong association between GERD on CRS in children, whereas studies on relationship between GERD and CRS in adults have produced conflicting results. On the one hand, Jecker et al reported that GERD, but not laryngopharyngeal reflux, was more commonly associated with CRS. Using a 24-h pH probe, Wong et al in a prospective
study of 40 adult patients with newly diagnosed CRS, found that 32.4% of their CRS patients had GERD. A similar result was reported by Loehrl et al21 studying postsurgical patients with refractory CRS. Vaezi et al22 and DiBaise et al23 reported that CRS patients benefited from aggressive PPI use as evidenced by subjective symptomatic improvement. On the other hand, some studies have not found such a relationship. Durmus et al24 found that reflux had no effect on nasal mucociliary clearance. Similarly, DeConde et al 25 reported that comorbid GERD had no impact on both baseline and postoperative quality of life for CRS patients undergoing endoscopic sinus surgery. Therefore, as concluded by 2 review studies, the association between the 2 diseases in adults has not been consistently demonstrated.26,27

| Characteristic      | Patients With GERD (N = 15,807) | Patients Without GERD (N = 47,421) |
|---------------------|----------------------------------|-------------------------------------|
| Age, years (Mean ± SD) | 50.87 ± 16.25                   | 49.47 ± 17.58                      |
| 18–44               | 5648                            | 16,968                             |
| 45–64               | 6750                            | 20,198                             |
| 65–74               | 1985                            | 5949                               |
| 75–84               | 1203                            | 3625                               |
| ≥85                 | 221                             | 681                                |
| Sex                 |                                  |                                     |
| Female              | 7649                            | 22,939                             |
| Male                | 8158                            | 24,482                             |
| Comorbidities       |                                  |                                     |
| Asthma              | 1045                            | 3128                               |
| AR                  | 2569                            | 7711                               |
| OM                  | 296                             | 880                                |
| Adenotonsillitis    | 90                              | 259                                |
| AD                  | 285                             | 847                                |
| Pneumonia           | 743                             | 2239                               |
| Follow-up years (median, 95% CI) |                |                                     |
| CRS                 | 2.04 (1.78–2.26)                | 2.18 (1.94–2.32)                   |
| CRSsNP              | 2.01 (1.77–2.25)                | 2.21 (1.94–2.39)                   |
| CRSwNP              | 2.09 (1.50–2.53)                | 2.05 (1.51–2.37)                   |

AD = atopic dermatitis, AR = allergic rhinitis, CI = confidence interval, CRS = chronic rhinosinusitis, CRSsNP = chronic rhinosinusitis without nasal polyps, CRSwNP = Chronic rhinosinusitis with nasal polyps, GERD = gastroesophageal reflux disease, OM = otitis media, SD = standard deviation.

TABLE 2. Crude and Adjusted Hazard Ratios for CRS Subtypes Between Patients With GERD and Without GERD

| CRS Subtype          | Patients With GERD (N = 15,807) | Patients Without GERD (N = 47,421) |
|----------------------|----------------------------------|-------------------------------------|
| Yes/total (%)        |                                  |                                     |
| CRSsNP (n = 771)     |                                  |                                     |
| Crude HR (95% CI)    | 2.47 (2.14–2.85)                | 1.00                               |
| Adjusted HR (95% CI) | 2.48 (2.15–2.86)                | 1.00                               |
| CRSwNP (n = 193)     |                                  |                                     |
| Yes/total (%)        | 71/15,807 (0.45)                | 122/47,421 (0.26)                  |
| Crude HR (95% CI)    | 1.84 (1.37–2.47)                | 1.00                               |
| Adjusted HR (95% CI) | 1.85 (1.37–2.48)                | 1.00                               |
| CRS (n = 964)        |                                  |                                     |
| Yes/total (%)        | 406/15,807 (2.57)               | 558/47,421 (1.18)                  |
| Crude HR (95% CI)    | 2.35 (2.07–2.67)                | 1.00                               |
| Adjusted HR (95% CI) | 2.36 (2.08–2.68)                | 1.00                               |

HR = hazard ratio; CI = confidence interval, CRS = chronic rhinosinusitis, CRSsNP = chronic rhinosinusitis without nasal polyps, CRSwNP = Chronic rhinosinusitis with nasal polyps, GERD = gastroesophageal reflux disease. Hazard ratios were calculated with the Cox proportional regression method (stratified by sex, age group, and index year).

*P < 0.001.

† Model adjusted for age, sex, asthma, allergic rhinitis, otitis media, adenotonsillitis, atopic dermatitis, and pneumonia.

AD = atopic dermatitis, AR = allergic rhinitis, CI = confidence interval, CRS = chronic rhinosinusitis, CRSsNP = chronic rhinosinusitis without nasal polyps, CRSwNP = Chronic rhinosinusitis with nasal polyps, GERD = gastroesophageal reflux disease, OM = otitis media, SD = standard deviation.
There are several possible reasons for the increased risk of CRS in GERD patients. First, pathogenic reflux causes frequent and prolonged exposure of gastric contents to the esophagus and may reach the nasopharynx. Changes in the homeostasis of sinonasal epithelium, which could occur as result of prolonged exposure to refluxate, can contribute importantly to the pathogenesis of CRS. We hypothesize that acid, pepsin, trypsin, and bile contained in refluxate might directly injure sinonasal epithelium as it does esophageal mucosa, which would result in epithelial barrier dysfunction and allow micro-organisms to flourish on the surface of mucosa. Further studies are needed to test this hypothesis. If so, the compromised epithelium could induce a series of immune responses, including production of epithelial-derived cytokines, which contribute to both innate and adaptive type 2 inflammations through the activation of toll-like receptors. The resulting tissue remodeling could then be responsible for the development of rhinosinusitis as well as nasal polyps. Another reason that might put GERD patients at risk for CRS is that a vagal nerve-mediated reflex arc might exist between respiratory mucosa of nose and sinus cavity and the esophagus. Wongs reported that esophageal para-sympathetic receptors in GERD patients were hyper-responsive to different stimuli, such as acid provocation or mechanical distention. This phenomenon can be partially explained by increased expression of nerve growth factor and transient receptor potential vanilloid type 17. Such a esophageal-nasal reflex could be responsible for nasal congestion, excessive nasal secretions, and continuous postnasal drainage. Synergistically with other predisposing factors, neuropathic rhinitis could potentially contribute to the development of CRS in people with GERD. Still another possible reason for the increased risk of CRS in this population might be related to the association between GERD and eosinophilic esophagitis. This immune-mediated esophageal disease is characterized by esophageal eosinophilia resulting from overexpression of several pro-inflammatory mediators, including thymic stromal lymphopoeitin, a key regulator in the development of CRS. In some cases, GERD occurs with this histologic feature of esophageal eosinophilia, and thus it may be that GERD can lead to CRS through a complex immunologic mechanism linking upper respiratory and esophageal mucosa.

Interestingly, after adjusting for demographic characteristics and selected comorbidities, this study found that patients with GERD were 2.48- and 1.85-times more likely than controls to have been subsequently diagnosed with CRS without nasal polyps and CRS with nasal polyps, respectively. As was found by the GHS study, the association between newly diagnosed GERD and risk of newly diagnosed CRS without nasal polyps was stronger than the association between GERD and CRS with nasal polyps. Given the multiplicity and complexity of the pathogeneses of GERD and CRS, consistent evidence addressing the phenomenon is limited. One possible reason for the difference in risk estimates is that the GERD’s inflammatory profile resembles that of CRS without nasal polyps more closely than the profile of CRS with nasal polyps. It is also worth noting that the risk estimate values in the present study were even higher than those reported in the GHS study, especially for those with CRS without nasal polyps. These differences could be explained by differences in race and geographic region, but they could be related by how GERD was defined by the 2 studies. GHS’s GERD cohort was selected based exclusively on practitioner-coded ICD-9 codes, whereas our study selected patients based on prescriptions of PPI, which we used as a surrogate for a diagnosis of GERD. In Taiwan, the National
TABLE 3. Analysis of Risk Factors for CRS Without Nasal Polyps in Patients With GERD (N = 335)

| Variables | Univariate Analysis, Crude HR (95% CI) | Multivariable Analysis, Adjusted HR 1 (95% CI) |
|-----------|----------------------------------------|-----------------------------------------------|
| Age, y    |                                        |                                               |
| 18–44     | 1.00                                   | 1.00                                          |
| 45–64     | 1.52 (1.06, 3.32)*                     | 1.59 (1.24, 2.04)**                          |
| 65–74     | 1.50 (0.59, 3.17)                      | 1.56 (1.10, 2.21)**                          |
| 75–84     | 0.99 (1.01, 5.43)†                     | 0.96 (0.58, 1.58)                           |
| ≥85       | —                                      | —                                            |
| Sex       |                                        |                                               |
| Female    | 1.00                                   | 1.00                                          |
| Male      | 1.09 (0.88, 1.35)                      | 1.16 (0.93, 1.44)                           |
| Comorbidities |                                    |                                               |
| Asthma    |                                        |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 1.68 (1.18–2.38)**                     | 1.08 (0.75, 1.56)                           |
| AR        |                                        |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 3.18 (2.55–3.96)**                     | 3.15 (2.50–3.96)**                          |
| OM        |                                        |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 1.65 (0.88–3.10)                      | 1.44 (0.77, 2.70)                           |
| Adenotonsillitis |                              |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 2.60 (1.07–6.29)*                      | 2.19 (0.91, 5.32)                           |
| AD        |                                        |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 1.71 (0.91–3.21)                      | 1.54 (0.82, 2.90)                           |
| Pneumonia |                                        |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 1.32 (0.83–2.10)                      | 1.14 (0.71, 1.84)                           |

AD = atopic dermatitis, AR = allergic rhinitis, CI = confidence interval, CRS = chronic rhinosinusitis, GERD = gastroesophageal reflux disease, HR = hazard ratio, OM = otitis media.

* P < 0.05.
** P < 0.01.
*** P < 0.001.
1 Model adjusted for age, sex, and comorbidities.

TABLE 4. Analysis of Risk Factors for CRS With Nasal Polyps in Patients With GERD (N = 71)

| Variables | Univariate analysis, Crude HR (95% CI) | Multivariable Analysis, Adjusted HR 1 (95% CI) |
|-----------|----------------------------------------|-----------------------------------------------|
| Age, y    |                                        |                                               |
| 18–44     | 1.00                                   | 1.00                                          |
| 45–64     | 1.87 (1.06, 3.32)*                     | 1.94 (1.09, 3.44)*                           |
| 65–74     | 1.37 (0.59, 3.17)                      | 1.37 (0.59, 3.18)                           |
| 75–84     | 2.34 (1.01, 5.43)                      | 2.08 (0.88, 4.89)                           |
| ≥85       | —                                      | —                                            |
| Sex       |                                        |                                               |
| Female    | 1.00                                   | 1.00                                          |
| Male      | 2.10 (1.27, 3.47)**                     | 2.16 (1.31, 3.58)**                          |
| Comorbidities |                                    |                                               |
| Asthma    |                                        |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 1.56 (0.72, 3.41)                      | 1.10 (0.48, 2.52)                           |
| AR        |                                        |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 2.31 (1.40, 3.82)**                     | 2.34 (1.39, 3.94)**                          |
| OM        |                                        |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 1.54 (0.38, 6.30)                      | 1.45 (0.35, 5.93)                           |
| Adenotonsillitis |                              |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | —                                      | —                                            |
| AD        |                                        |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 0.79 (0.11, 5.66)                      | 0.71 (0.10, 5.16)                           |
| Pneumonia |                                        |                                               |
| No        | 1.00                                   | 1.00                                          |
| Yes       | 2.03 (0.88, 4.69)                      | 1.64 (0.68, 3.94)                           |

AD = atopic dermatitis, AR = allergic rhinitis, CI = confidence interval, CRS = chronic rhinosinusitis, GERD = gastroesophageal reflux disease, HR = hazard ratio, OM = otitis media.

* P < 0.05.
** P < 0.01.
1 Model adjusted for age, sex, and comorbidities.

Health Insurance program covers the use of PPIs only for patients with reflux erosive esophagitis proven by panendoscopic examination. The duration of use depends on the severity of esophagitis. Prescription of PPIs to the nonerosive reflux disease is only indicated after esophageal pH-meter monitoring. However, this diagnostic methodology is not commonly utilized in the current medical practice in Taiwan. These differences in cohort selection may partially explain the differences in risks estimated by the two studies. This difference in selection would also result in difference the distributions of GERD subgroups. A greater proportion of the GERD population in our study may have had erosive esophagitis, and so macroscopic esophageal mucosal breach as well as high-grade inflammation involved in this disease may contribute importantly to the development of CRS.32 A well-designed prospective study is needed to compare the effects on erosive and nonerosive reflux disease on the development of CRS with and without polyps.

This study has several limitations. One limitation was that we could not obtain information on the number and severity of symptoms as well as endoscopic findings from the administrative database we used, and thus it was not possible to determine the relationship between severity of GERD and CRS. Another limitation is that all GERD patients in this study were receiving PPI treatment, so it was not possible to determine whether the risk of developing CRS was modifiable by PPI treatment. In addition, we sampled the patients of the 2 diseases based on order of priority. Because both conditions require a period of time to develop, we could not exclude the coexistence or inverse timing sequence possibilities of the 2 conditions. Still another limitation is that we did not have access to information for some variables that contribute to propensity to CRS, such as exposure to cigarette smoke, air pollution, chemical particles, and vapors.15

CONCLUSIONS

In conclusion, patients with GERD in this population-based study were at greater risk of developing CRS, especially of CRS without nasal polyps, compared with patients without GERD. Physician may want to keep the possibility of the...
development of CRS in mind when treating patients with GERD. Further studies may want to focus on the relationship between the types or severities of GERD and CRS.

REFERENCES

1. El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–880.

2. Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23:8–22.

3. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920.

4. Hom C, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2013;42:71–91.

5. El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with eosinophilic gastroenteritis in United States military veterans. Gastroenterology. 1997;113:755–760.

6. Poe RH, Kallay MC. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. Chest. 2003;123:679–684.

7. Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012;3: preceding table of contents, 1–298.

8. Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg. 2007;137: S1–S31.

9. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol. 2004;114:155–212.

10. Van Zele T, Claes S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61:1280–1289.

11. Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital Health Stat. 2014:1–161.

12. Halawi AM, Smith SS, Chandra RK. Chronic rhinosinusitis: epidemiology and cost. Allergy Asthma Proc. 2013;34:328–334.

13. Bhattacharyya N. Contemporary assessment of the disease burden of sinusitis. Am J Rhinol Allergy. 2009;23:392–395.

14. Tan BK, Chandra RK, Pollak J, et al. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;131:1350–1360.

15. Min JY, Tan BK. Risk factors for chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. 2015;15:1–13.

16. Chandra RK, Lin D, Tan B, et al. Chronic rhinosinusitis in the setting of other chronic inflammatory diseases. Am J Otolaryngol. 2011;32:388–391.

17. Mahdavinia M, Grammer LC. 3rd. Chronic rhinosinusitis and age: is the pathogenesis different? Expert Rev Antivir Infect Ther. 2013;11:1029–1040.

18. Contencin P, Maourage C, Ployet MJ, et al. Gastroesophageal reflux and ENT disorders in childhood. Int J Pediatr Otorhinolaryngol. 1995;32(Suppl):S135–S144.

19. Jecker P, Orloff LA, Wohlfeil M, et al. Gastroesophageal reflux disease (GERD), extraesophageal reflux (EER) and recurrent chronic rhinosinusitis. Eur Arch Otorhinolaryngol. 2006;263:664–667.

20. Wong IW, Omari TI, Myers JC, et al. Nasopharyngeal pH monitoring in chronic sinusitis patients using a novel four channel probe. Laryngoscope. 2004;114:1582–1585.

21. Loehrl TA, Samuels TL, Poetker DM, et al. The role of extraesophageal reflux in medically and surgically refractory rhinosinusitis. Laryngoscope. 2012;122:1425–1430.

22. Vaezi MF, Hagaman DD, Slaughter JC, et al. Proton pump inhibitor therapy improves symptoms in post-nasal drainage. Gastroenterology. 2010;139:1887–1893.

23. DiBase JK, Olosua BF, Hueter JV, et al. Role of GERD in chronic resistant sinusitis: a prospective, open label, pilot trial. Am J Gastroenterol. 2002;97:843–850.

24. Durmus R, Naboglu B, Tek A, et al. Does reflux have an effect on nasal mucociliary transport? Acta Otolaryngol. 2010;130:1053–1057.

25. DeConde AS, Mace JC, Smith TL. The impact of comorbid gastroesophageal reflux disease on endoscopic sinus surgery quality-of-life outcomes. Int Forum Allergy Rhinol. 2014;4:663–669.

26. Katle EJ, Hatlebakk JG, Steinsvåg S. Gastroesophageal reflux and rhinosinusitis.Curr Allergy Asthma Rep. 2013;13:218–223.

27. Flock EP, Kumar BN. Is there evidence to link acid reflux with chronic sinusitis or any nasal symptoms? A review of the evidence. Rhinology. 2011;49:11–16.

28. Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:236–242.

29. National Health Research Institutes. National health insurance research database. 2007. Available at: http://nhird.nhri.org.tw/en/Data_Subsets.html. Accessed May 12, 2015.

30. Schönler L, Ruth M, Jögi R, et al. Nocturnal GERD - a risk factor for rhinitis/rhinosinusitis: the RHINE study. Allergy. 2015;70:697–702.

31. Tieu DD, Peters AT, Carter RG, et al. Evidence for diminished levels of epithelial porcinein and calprotectin in chronic rhinosinusitis. J Allergy Clin Immunol. 2010;125:667–675.

32. Farré R. Pathophysiology of gastro-esophageal reflux disease: a role for mucosa integrity? Neurogastroenterol Motil. 2013;25:783–799.

33. Kato A, Schlemer RP. Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr Opin Immunol. 2007;19:711–720.

34. Wang X, Zhao C, Ji W, et al. Relationship of TLR2, TLR4 and tissue remodeling in chronic rhinosinusitis. Int J Clin Exp Pathol. 2015;8:1199–1212.

35. Wong IW, Rees G, Greiff L, et al. Gastroesophageal reflux disease and chronic sinusitis: in search of an esophageal-nasal reflex. Am J Rhinol Allergy. 2010;24:255–259.

36. Coffey CS, Mulligan RM, Schlosser RJ. Mucosal expression of nerve growth factor and brain-derived neurotrophic factor in chronic rhinosinusitis. Am J Rhinol Allergy. 2009;23:571–574.

37. Yu X, Hu Y, Yu S. Effects of acid on vagal nociceptive afferent subtypes in guinea pig esophagus. Am J Physiol Gastrointest Liver Physiol. 2014;307:G471–G478.

38. Cheng E, Souza RF, Spechler SJ. Eosinophilic esophagitis: interactions with gastroesophageal reflux disease. Gastroenterol Clin North Am. 2014;43:243–256.

39. Noti M, Wojno ED, Kim BS, et al. Thymic stromal lymphopoeitin-elicited basophil responses promote eosinophilic esophagitis. Nat Med. 2013;19:1005–1013.

40. Boita M, Garzaro M, Raimondo L, et al. The expression of TSLP immunological determinants. Gut. 2002;50:451–459.